Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Tumour-associated high endothelial venules drive portal-specific immune evasion in lymph nodes via ALOX12.

Nature communications·2026

Same author

Integrating ctDNA Dynamics and Sequential Organoid Drug Screening Enhances Breast Cancer Treatment Efficacy.

Cancer research·2025

Same author

An Approach for Differential Diagnosis of Breast Tumors by ctDNA Methylation Sequencing.

Cancer medicine·2025

Same author

Tumor-Specific Protein Induced in Situ Self-Assembly of Peptide Drugs for Synergistic Mitochondria Disruption.

Advanced materials (Deerfield Beach, Fla.)·2024

Same author

NAT10/ac4C/JunB facilitates TNBC malignant progression and immunosuppression by driving glycolysis addiction.

Journal of experimental & clinical cancer research : CR·2024

Same author

Deciphering cell-cell communication at single-cell resolution for spatial transcriptomics with subgraph-based graph attention network.

Nature communications·2024

Search research articles

Related Experiment Video

Updated: May 15, 2026

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Integrated Proteogenomic Characterization Identifies Breast Cancer Immune Subgroups and Subtype-Specific Therapeutic

Guozheng Li^1,2, Yihai Chen¹, Yong Liu³

¹Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin 150040, China.

Research (Washington, D.C.)

|May 14, 2026

Summary

This study reveals three breast cancer subtypes by integrating multiomics data. Understanding protein lactylation and phosphorylation interplay offers new strategies for precision immunotherapy.

More Related Videos

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Related Experiment Videos

Last Updated: May 15, 2026

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Area of Science:

Oncology
Immunology
Metabolomics

Background:

Breast cancer heterogeneity complicates treatment.
Immunotherapy benefits a limited patient subset due to tumor microenvironment diversity.
Posttranslational modifications regulate cellular signaling, metabolism, and immunity.

Purpose of the Study:

To create a multiomics immune-metabolic atlas of breast cancer.
To define breast cancer subtypes based on immune and metabolic profiles.
To investigate the role of posttranslational modifications in breast cancer.

Main Methods:

Integrated analysis of genomics, transcriptomics, proteomics, lactylomics, and phosphoproteomics.
Immune infiltration profiling to identify subtypes.
Analysis of posttranslational modifications, including protein and histone lactylation and phosphorylation.

Main Results:

Defined 3 immune-related breast cancer subtypes with distinct metabolic states and mutational landscapes.
Identified crosstalk between protein lactylation and phosphorylation regulating glycolysis and immune response.
Discovered subtype-specific histone lactylation patterns linked to therapeutic response.

Conclusions:

The developed atlas provides a framework for understanding breast cancer immune-metabolic regulation.
Interplay of lactylation and phosphorylation is crucial for metabolic reprogramming and immune modulation.
Findings guide the development of subtype-specific precision immunotherapeutic strategies for breast cancer.